Royal Bank Of Canada Equillium, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.73 - $3.0 $83 - $342	-114 Reduced 79.72%	29 $0
Q4 2023 Feb 14, 2024	SELL	$0.48 - $0.74 $74 - $115	-156 Reduced 52.17%	143 $0
Q3 2023 Nov 14, 2023	SELL	$0.72 - $0.9 $120 - $151	-168 Reduced 35.97%	299 $0
Q2 2023 Aug 14, 2023	BUY	$0.49 - $0.79 $228 - $368	467 New	467 $0
Q3 2022 Nov 14, 2022	BUY	$1.93 - $3.14 $214 - $348	111 New	111 $0
Q3 2021 Nov 15, 2021	SELL	$4.84 - $6.91 $484 - $691	-100 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.11 - $7.64 $511 - $764	100 New	100 $1,000

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $25.8M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.